This site uses cookies. By using this site you agree to receiving cookies. View Policy.

105%

Inspira Pharma is developing a potential new therapy for COVID-19. The active molecules being tested are plant-based and have shown an ability to destroy the SARS-CoV-2 virus in the lab. Funds raised will be used to test clinical formulations and prove safety and efficacy in humans.

  • Patent protected plant-based formulations (under license)
  • Proven to kill SARS-CoV-2 in early stage lab testing
  • Platform technology - Potential for a range of lung diseases
  • Working with leading research organisations

Idea

There's still no cure for COVID-19. “Vaccines will never be a 100% solution... it’s almost certain that we will continue to have people falling seriously ill with COVID for a long time, perhaps forever.” (Prof. Peter Horby, Oxford University).

Our team were conducting research into wound care with another biomedical firm but, when COVID-19 hit, they looked to pivot the technology through Inspira to tackle this challenge. They discovered that the molecules in the formulations might be able to attack the SARS-CoV-2 spike proteins.

In lab tests, our formulations killed over 95% of the SARS-CoV-2 virus; now we want to test whether a COVID-19 patient could safely inhale our formulations directly into the lungs as an effective treatment.

So far we've secured cornerstone investment from biotech angel investors & a Singaporean VC, we’re now offering retail investors the opportunity to invest alongside them! Funds raised will be used to test our formulations as a potential new drug. This will include further laboratory analysis, safety testing, & preparation for human trials.

We believe our technology has further potential for a number of other respiratory infections. We plan to test our formulations against cystic fibrosis, influenza & the common cold in coming months.

COVID-19 thrives in a crowd, wouldn't it be amazing if the crowd could come together to fight back against the pandemic.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Inspira Pharmaceuticals pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investing in start-ups and early stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Crowdcube is targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions. You will only be able to invest via Crowdcube once you are registered as sufficiently sophisticated. Please click here to read the full Risk Warning.

Crowdcube is authorised and regulated by the Financial Conduct Authority (FCA) and the Comisión Nacional del Mercado de Valores (CNMV). This page has been approved by Crowdcube. Pitches for investment are not offers to the public and investments can only be made by members of crowdcube.com on the basis of information provided in the pitches by the companies concerned. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Inspira Pharmaceuticals has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Seed Enterprise Investment Scheme (SEIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 50 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.